EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy - 10/10/23
Doi : 10.1016/j.jaad.2023.06.057
Teresa Amaral, MD, PhD a, b, Oltin Tiberiu Pop, MD, PhD c, Eftychia Chatziioannou, MD a, Tobias Sinnberg, Dr rer nat a, b, d, Heike Niessner, Dr rer nat a, b, Jing Zhao, MSc e, Sandra Stephanie Ring, PhD f, Markus Joerger, MD, PhD g, Christopher Schroeder, MD h, Sorin Armeanu-Ebinger, Dr rer nat h, Antonio Cozzio, MD, Dr sc nat i, Ulrike Leiter, MD a, Ioannis Thomas, MD a, Wolfram Jochum, MD j, Claus Garbe, MD a, Stephan Forchhammer, MD a, Mitchell Levesque, PhD k, Joanna Mangana, MD k, Michael Hölzel, MD, PhD l, Reinhard Dummer, MD k, Christian M. Schürch, MD, PhD e, Andrea Forschner, MD a, Lukas Flatz, MD a, c, i, ⁎ 
a Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Tübingen, Germany
b Cluster of Excellence iFIT (EXC 2180), Tübingen, Germany
c Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
d Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany
e Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany
f Institute of Clinical Chemistry and Pathobiochemistry, Central Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany
g Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
h Institute for Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany
i Department of Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland
j Institute of Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland
k Department of Dermatology, University Hospital of Zürich, University of Zürich, Zürich, Switzerland
l Institute of Experimental Oncology, University Hospital of Bonn, Bonn, Germany
∗Correspondence to: Lukas Flatz, MD, Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Liebermeisterstrasse 25, 72076 Tübingen, GermanyCenter for DermatooncologyDepartment of DermatologyEberhard Karls University of TübingenLiebermeisterstrasse 25Tübingen72076Germany
| Drs Amaral, Pop, Forschner, and Flatz contributed equally to this article. |
|
| Funding sources: This work was supported by Kantonsspital St. Gallen (FOKO-Nr. 20/08), and Swiss Cancer League (project ID: KFS-5700-08-2022-R). |
|
| IRB approval status: This study was approved by both institutions’ ethics committees (Eberhard Karls University of Tübingen, approval number – 606/2020BO and University of Zürich, approval number – EK647), and was conducted following consensus ethical principles derived from international ethical guidelines, including the Declaration of Helsinki. |
|
| Patient consent: Patients included in the publication have signed the Informed Consent in their respective centers following approval by the respective ethics committees (Eberhard Karls University of Tübingen, approval number – 606/2020BO and University of Zürich, approval number – EK647) allowing the use of anonymized medical data and tumor samples for investigation. |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89 - N° 5
P. 1072-1074 - novembre 2023 Retour au numéro
Article précédent
- Acquired, bilateral nevus of Ota-like macules in children: Clinical findings in 46 patients
- Hongjin Wu, Min Li, Shen Wang, Wen Qian, Dan Luo
- Serum levels of S-100 protein are directly proportional to the size, number, thickness and degree of cellularity of congenital melanocytic nevi
- Alejandra Tomás-Velázquez, Juan Carlos López-Gutiérrez, Miguel Reyes-Múgica, Claudia M. Salgado, Sandra Hervás-Stubbs, Carlos de Andrea, Dipanjan Basu, Eva M. Andrés, Paloma Triana, Carmen Ceballos, Gabriel Reina, Pedro Redondo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?